Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma

Tumor Biology

Volumn 36, Issue 7, 2015, Pages 5273-5281

  Zhang, Xiaohua ^a   Wang, Xianjin ^a   Xu, Tianyuan ^a   Zhong, Shan ^a   Shen, Zhoujun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Malignant; mTORC1; mTORC2; Paragangliomas; Pheochromocytoma

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; RAPAMYCIN; RAPAMYCIN INSENSITIVE COMPANION OF MAMMALIAN TARGET OF RAPAMYCIN; REGULATORY ASSOCIATED PROTEIN OF MAMMALIAN TARGET OF RAPAMYCIN; S6 KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CARRIER PROTEIN; INDOLE DERIVATIVE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MTOR PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; PURINE DERIVATIVE; RICTOR PROTEIN, HUMAN; RPTOR PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MALIGNANT PHEOCHROMOCYTOMA; MIGRATION INHIBITION; MOUSE; MTT ASSAY; NONHUMAN; OUTCOME ASSESSMENT; PARAGANGLIOMA; PC12 CELL LINE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; WOUND HEALING; ADRENAL GLAND NEOPLASMS; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; DRUG SCREENING; GENETICS; PATHOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADRENAL GLAND NEOPLASMS; ANIMALS; CARRIER PROTEINS; HUMANS; INDOLES; MICE; MULTIPROTEIN COMPLEXES; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PURINES; RNA, SMALL INTERFERING; SIROLIMUS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938212786     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3187-7     Document Type: Article

References (24)

1. Favier J, Igaz P, Burnichon N, et al. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma. Endocr Pathol. 2012;23:34–42.
2. Lowery AJ, Walsh S, McDermott EW, et al. Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas. Oncologist. 2013;18:391–407.
3. Druce MR, Kaltsas GA, Fraenkel M, et al. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res. 2009;41:697–702.
4. Jimenez C, Rohren E, Habra MA, et al. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep. 2013;15:356–71.
5. Buzzoni R, Pusceddu S, Damato A, et al. Malignant pheochromocytoma and paraganglioma: future considerations for therapy. Q J Nucl Med Mol Imaging. 2013;57:153–60.
6. Parenti G, Zampetti B, Rapizzi E, et al. Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. J Oncol. 2012;2012:872713.
7. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nature reviews. Mol Cell Biol. 2011;12:21–35.
8. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med. 2005;11:353–61.
9. Betz C, Hall MN. Where is mTOR and what is it doing there? J Cell Biol. 2013;203:563–74.
10. Sun SY. mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett. 2013;340:1–8.
11. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122:3589–94.
12. Sparks CA, Guertin DA. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene. 2010;29:3733–44.
13. Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009;7:e38.
14. Yu K, Shi C, Toral-Barza L, et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 2010;70:621–31.
15. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009;284:8023–32.
16. Janes MR, Limon JJ, So L, et al. Fruman, Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med. 2010;16:205–13.
17. Zhang YJ, Duan Y, Zheng XF. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today. 2011;16:325–31.
18. Li H, Lin J, Wang X, et al. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. Breast Cancer Res Treat. 2012;134(3):1057–66.
19. Altman JK, Szilard A, Goussetis DJ, et al. Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20:2400–9.
20. Jordan NJ, Dutkowski CM, Barrow D, et al. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Breast Cancer Research BCR. 2014;16:R12.
21. Houghton PJ. Everolimus. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16:1368–72.
22. Thoreen CC, Sabatini DM. Rapamycin inhibits mTORC1, but not completely. Autophagy. 2009;5:725–6.
23. Carew JS, Kelly KR, Nawrocki ST. Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol. 2011;6:17–27.
24. Xing X, Zhang L, Wen X, et al. PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway. Anticancer Drugs. 2014;25(10):1129–40.